Fact based stock research
Zhejiang Hisun Pharmaceutical (SHSE:600267)


Zhejiang Hisun Pharmaceutical stock research in summary

hisunpharm.com


Zhejiang Hisun Pharmaceutical shares have a BUY rating. They are good value and show above average growth, but are riskily financed. We recommend buying and holding Zhejiang Hisun Pharmaceutical shares.


Latest Obermatt Ranks


Country China
Industry Pharmaceuticals
Index SSE Composite
Size class Medium

November 2, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Zhejiang Hisun Pharmaceutical

RESEARCH HISTORY 2015 2016 2017 2018
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 2-Nov-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better Zhejiang Hisun Pharmaceutical is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2015 2016 2017 2018
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 2-Nov-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Zhejiang Hisun Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Financial reporting date of Growth Rank: 30-Jun-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Zhejiang Hisun Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Financial reporting date of Safety Rank: 30-Jun-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Zhejiang Hisun Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Zhejiang Hisun Pharmaceutical from November 2, 2018.